Skip to main content
Premium Trial:

Request an Annual Quote

Bridge Bio and Finnzymes Form PCR Venture to Sell PCR Technologies

NEW YORK (GenomeWeb News) — Finnzymes Instruments and Bridge Bioscience have created a joint venture and started a new company to sell certain PCR technologies.
 
Under the agreement, Bridge Bio will transfer all of the physical assets and patents in its PCR business to the new company, called BioInnovations Oy, which will be controlled by Finnzymes.
 
According to BridgeBio’s website, the company’s PCR portfolio includes reagents and products for electroporation, electrophoresis, and transfection.
 
Finnzymes, a PCR and RNA technologies company based in Esposo, Finland, has purchased a majority stake in the new company.
 
BioInnovations Oy will be based in Finland, but will have a US subsidiary called BioInnovations Inc., according to Bridge Bio President Bruce Turner.
 
Turner will take over as CEO of BioInnovations Inc., and will serve as COO of BioInnovations Oy.
 
Financial terms of the agreement were not released.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.